Cancer biomarkers are quantifiable markers of biological processes or disease states that yield important information for diagnosis, prognosis, and treatment choice. The session "Cancer Biomarkers" highlights recent findings and developments of biomarkers in precision oncology.".
Biomarkers may be genetic mutations, proteins, metabolites, or cell-free circulating tumor DNA representing the existence or development of cancer. Biomarkers are critical in early detection, treatment response prediction, disease recurrence monitoring, and individualized therapy guidance. The development of molecular profiling and high-throughput technologies has broadened the detection of new biomarkers, enhancing clinical decision-making.
This session also discusses the incorporation of biomarkers into clinical practice. For instance, targeted therapies and immunotherapies may be chosen depending on certain biomarker profiles, such that the patient gets the best treatment possible with fewer adverse effects. New tools like liquid biopsies and AI-based analysis are improving biomarker testing accuracy and access.
Participants will learn about the biology, clinical use, and emerging trends of cancer biomarkers. This session is notable for how biomarkers are revolutionizing oncology by facilitating earlier diagnosis, more targeted treatment, and improved monitoring of disease progression, ultimately improving cancer outcomes globally.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
